Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PrEP
Pharma
Gilead's PrEP shows early promise in once-yearly dosing
Once-yearly lenacapavir achieved blood concentrations that exceeded those associated with the strong efficacy that its twice-yearly version showed.
Angus Liu
Mar 11, 2025 2:30pm
Gilead charts course for long-acting PrEP launch
Feb 12, 2025 9:12am
GSK questions Gilead's potential dominance of the PrEP market
Feb 6, 2025 2:20pm
GSK raises long-term sales goal—again—despite vaccines woes
Feb 5, 2025 11:06am
Gilead inks licensing deals to boost lenacapivir access
Oct 2, 2024 3:14pm
Gilead races toward filings for long-acting PrEP after trial win
Sep 12, 2024 11:45am
